Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adverse symptoms attributed to e-cigarettes over six months among participants of a randomized controlled trial testing nicotine freebase e-cigarettes for smoking cessation - Secondary analysis of the ESTxENDS trial.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco·2026

Same author

Association between duration or intensity of tobacco smoking and olfactory function: A cross-sectional study among smokers willing to quit smoking.

Tobacco induced diseases·2025

Same author

Pulmonary Hypertension Associated with Interstitial Lung Disease: A Review on Diagnosis and Treatment with a Focus on Emerging Therapies.

Respiration; international review of thoracic diseases·2025

Same author

Pulmonary Hypertension in the Field of Hematological and Oncological Diseases.

Respiration; international review of thoracic diseases·2025

Same author

Efficacy of e-cigarettes for smoking cessation in populations with psychiatric and/or substance use problems: A secondary analysis of a randomized controlled trial.

Tobacco prevention & cessation·2025

Same author

Smoking cessation assistance among pneumologists and thoracic surgeons in Switzerland: a national survey.

Frontiers in health services·2024

Search research articles

Related Experiment Video

Updated: Jun 28, 2025

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

[Progressive pulmonary Fibrosis].

Rebekka Kleiner¹, Susanne Pohle¹

¹Kantonsspital St. Gallen Klinik für Pneumologie und Schlafmedizin Rorschacher Str. 95 9007 St. Gallen.

Therapeutische Umschau. Revue Therapeutique

|April 24, 2024

Summary

This summary is machine-generated.

Progressive pulmonary fibrosis, a group of lung diseases, presents early symptoms like cough and dyspnea. New antifibrotic drugs offer therapeutic options for managing this condition.

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

Related Experiment Videos

Last Updated: Jun 28, 2025

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

Area of Science:

Pulmonology
Radiology
Pharmacology

Background:

Interstitial lung diseases (ILD) often manifest with early symptoms of cough and dyspnea on exertion.
Thoracic imaging, especially computed tomography, is crucial for early detection of lung structural changes in ILD.
Progressive pulmonary fibrosis encompasses a heterogeneous group of ILDs with similar fibrotic progression.

Purpose of the Study:

To highlight the importance of early diagnosis and management of progressive pulmonary fibrosis.
To emphasize the interdisciplinary approach required for managing these conditions, akin to Idiopathic Pulmonary Fibrosis (IPF).
To introduce novel therapeutic strategies, including antifibrotic drugs.

Main Methods:

Review of current diagnostic imaging techniques (CT scans) for interstitial lung diseases.
Analysis of disease progression patterns in various forms of pulmonary fibrosis.
Evaluation of emerging antifibrotic therapies.

Main Results:

Early symptom recognition (cough, dyspnea) and advanced imaging are key for timely diagnosis.
Progressive pulmonary fibrosis requires a multidisciplinary management strategy.
Antifibrotic drugs represent a significant advancement in treatment options.

Conclusions:

Effective management of progressive pulmonary fibrosis necessitates early detection and a collaborative, interdisciplinary approach.
Antifibrotic medications offer new hope for patients with progressive pulmonary fibrosis.
Continued research into ILDs and their treatments is essential.